ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia

New England Journal of Medicine

Volumn 348, Issue 18, 2003, Pages 1764-1775

  Crespo, Marta ^a   Bosch, Francesc ^a   Villamor, Neus ^a   Bellosillo, Beatriz ^a   Colomer, Dolors ^a   Rozman, María ^a   Marcé, Silvia ^a   López Guillermo, Armando ^a   Campo, Elies ^a   Montserrat, Emili ^a  

^a HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE ZAP 70; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; B LYMPHOCYTE; CELL LINE; CELL STRAIN; CHRONIC LYMPHATIC LEUKEMIA; DAUDI CELL; DISEASE COURSE; DISEASE MARKER; FLOW CYTOMETRY; GENE MUTATION; HUMAN; HUMAN CELL; IMMUNOGLOBULIN VARIABLE REGION; IMMUNOHISTOCHEMISTRY; LEUKEMIA CELL; LEUKEMIA CELL LINE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RAJI CELL; SPAIN; SURVIVAL; T LYMPHOCYTE; WESTERN BLOTTING;

ADP-RIBOSYL CYCLASE; ANTIGENS, CD; ANTIGENS, CD38; DISEASE PROGRESSION; FLOW CYTOMETRY; GENES, IMMUNOGLOBULIN; HUMANS; IMMUNOGLOBULIN HEAVY CHAINS; IMMUNOGLOBULIN VARIABLE REGION; LEUKEMIA, LYMPHOCYTIC, CHRONIC; MEMBRANE GLYCOPROTEINS; MUTATION; PROGNOSIS; PROTEIN-TYROSINE KINASES; RECEPTORS, ANTIGEN, T-CELL; SURVIVAL ANALYSIS; ZAP-70 PROTEIN-TYROSINE KINASE;

EID: 0037406968     PISSN: 00284793     EISSN: None     Source Type: Journal    
DOI: 10.1056/NEJMoa023143     Document Type: Article

References (34)

1. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical staging of chronic lymphocytic leukemia. Blood 1975;46:219-34.
2. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48: 198-206.
3. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995;333: 1052-7. [Erratum, N Engl J Med 1995;333: 1515.]
4. Caligaris-Cappio F, Hamblin TJ. B-cell chronic lymphocytic leukemia: a bird of a different feather. J Clin Oncol 1999;17:399-408.
5. Montserrat E. Classical and new prognostic factors in chronic lymphocytic leukemia: where to now? Hematol J 2002;3:7-9.
6. Döhner H, Stilgenbauer S, Benner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000;343:1910-6.
7. Fais F, Ghiotto F, Hashimoto S, et al. Chronic lymphocytic leukemia B cells express restricted sets of mutated and unmutated antigen receptors. J Clin Invest 1998; 102:1515-25.
8. Damle RN, Wasil T, Fais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999;94: 1840-7.
9. Schroeder HW Jr, Dighiero G. The pathogenesis of chronic lymphocytic leukemia: analysis of the antibody repertoire. Immunol Today 1994;15:288-94.
10. Oscier DG, ThompsettA, Zhu D, Stevenson FK. Differential rates of somatic hypermutation in V(H) genes among subsets of chronic lymphocytic leukemia defined by chromosomal abnormalities. Blood 1997; 89:4153-60.
11. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999;94:1848-54.
12. Rajewsky K. Clonal selection and learning in the antibody system. Nature 1996; 381:751-8.
13. Stilgenbauer S, Bullinger L, Lichter P, Dohner H. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course. Leukemia 2002;16:993-1007.
14. Lin K, Sherrington PD, Dennis M, Matrai Z, Cawley JC, Pettitt AR. Relationship between p53 dysfunction, CD38 expression, and IgV(H) mutation in chronic lymphocytic leukemia. Blood 2002;100:1404-9. [Erratum, Blood 2002;100:2291.]
15. Klein U, Tu Y, Stolovitzky GA, et al. Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med 2001;194:1625-38.
16. Rosenwald A, Alizadeh AA, Widhopf G, et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001;194:1639-47.
17. Chen L, Widhopf G, Huynh L, et al. Expression of ZAP-70 is associated with increased B-cell receptor signaling in chronic lymphocytic leukemia. Blood 2002;100: 4609-14.
18. Chan AC, Irving BA, Fraser JD, Weiss A. The zeta chain is associated with a tyrosine kinase and upon T-cell antigen receptor stimulation associates with ZAP-70, a 70-kDa tyrosine phosphoprotein. Proc Natl Acad Sci U S A 1991;88:9166-70.
19. Chan AC, Iwashima M, Turck CW, Weiss A. ZAP-70: a 70 kd protein-tyrosine kinase that associates with the TCR zeta chain. Cell 1992;71:649-62.
20. Vivier E, da Silva AJ, Ackerly M, et al. Association of a 70-kDa tyrosine phosphoprotein with the CD16: zeta:gamma complex expressed in human natural killer cells. Eur J Immunol 1993;23:1872-6.
21. Isakov N, Wange RL, Burgess WH, Watts JD, Aebersold R, Samelson LE. ZAP-70 binding specificity to T cell receptor tyrosinebased activation motifs: the tandem SH2 domains of ZAP-70 bind distinct tyrosine-based activation motifs with varying affinity. J Exp Med 1995;181:375-80.
22. Latour S, Veillette A. Proximal protein tyrosine kinases in immunoreceptor signaling. Curr Opin Immunol 2001;13:299-306.
23. Bellosillo B, Villamor N, Lopez-Guillermo A, et al. Spontaneous and drug-induced apoptosis is mediated by conformational changes of Bax and Bak in B-cell chronic lymphocytic leukemia. Blood 2002; 100:1810-6.
24. Swerdlow SH, Berger F, Isaacson PI, et al. Mature B-cell neoplasms: mantle cell lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. WHO Classification of Tumours. Lyons, France: IARC Press, 2001:168-70.
25. Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215.
26. Campbell MJ, Zelenetz AD, Levy S, Levy R. Use of family specific leader region primers for PCR amplification of the human heavy chain variable region gene repertoire. Mol Immunol 1992;29:193-203.
27. Deane M, Norton JD. Immunoglobulin heavy chain variable region family usage is independent of tumor cell phenotype in human B lineage leukemias. Eur J Immunol 1990;20:2209-17.
28. Cook GP, Tolinson IM. The human immunoglobulin VH repertoire. Immunol Today 1995;16:237-42.
29. Zweig MH, Campbell G. Receiver-operating characteristics (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993;39:561-77. [Erratum, Clin Chem 1993;39: 1589.]
30. SPSS advanced statistics, version 10.0.6. Chicago, SPSS, 1999 (software).
31. H gene mutational status, and loss or mutation of the p53 gene are independent prognostic factors. Blood 2002;100:1177-84.
32. Del Poeta G, Maurillo L, Venditti A, et al. Clinical significance of CD38 expression in chronic lymphocytic leukemia. Blood 2001; 98:2633-9.
33. Ibrahim S, Keating M, Do KA, et al. CD38 expression as an important prognostic factor in B-cell chronic lymphocytic leukemia. Blood 2001;98:181-6.
34. Hamblin TJ, Orchard JA, Gardiner A, Oscier DG, Davis Z, Stevenson FK. Immunoglobulin V genes and CD38 expression in CLL. Blood 2000;95:2455-7.